Functional genomics of PCOS: From GWAS to molecular mechanisms

Trends in Endocrinology and Metabolism

Volumn 26, Issue 3, 2015, Pages 118-124

  McAllister, Jan M ^a   Legro, Richard S ^a   Modi, Bhavi P ^b   Strauss, Jerome F ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genomics; GWAS; Hyperandrogenism; PCOS; Signaling; Theca

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); FOLLITROPIN; FOLLITROPIN RECEPTOR; INSULIN; INSULIN RECEPTOR; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; TRANSCRIPTION FACTOR GATA 6;

ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; ANDROGEN SYNTHESIS; COPY NUMBER VARIATION; DENND1A GENE; EXOME; FSHR GENE; FUNCTIONAL GENOMICS; GENE LOCUS; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HYPERANDROGENISM; INSR GENE; INSULIN METABOLISM; INSULIN RESISTANCE; INTRON; LHCGR GENE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; THECA CELL; VARIABLE NUMBER OF TANDEM REPEAT; FEMALE; GENETIC PREDISPOSITION; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84923580418     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.12.004     Document Type: Review

References (89)

1. Azziz R., et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006, 91:4237-4245.
2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19:41-47. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group.
3. De Leo V., et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception 2010, 82:276-280.
4. Azziz R., et al. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil. Steril. 2003, 79:932-937.
5. Azziz R., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2001, 86:1626-1632.
6. Gilling-Smith C., et al. Evidence for a primary abnormality in theca cell steroidogenesis in the polycystic ovarian syndrome. Clin. Endocrinol. 1997, 47:1158-1165.
7. Gilling-Smith C., et al. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 1994, 79:1158-1165.
8. Nelson V.L., et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 1999, 13:946-957.
9. Nelson V.L., et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2001, 86:5925-5933.
10. Wickenheisser J.K., et al. Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J. Clin. Endocrinol. Metab. 2000, 85:2304-2311.
11. Magoffin D.A. Ovarian enzyme activities in women with polycystic ovary syndrome. Fertil. Steril. 2006, 86(Suppl. 1):S9-S11.
12. Jakimiuk A.J., et al. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 2001, 86:1318-1323.
13. Wickenheisser J.K., et al. Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2005, 90:1720-1727.
14. Nelson-Degrave V.L., et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol. Endocrinol. 2005, 19:379-390.
15. Wickenheisser J.K., et al. Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol. Endocrinol. 2004, 18:588-605.
16. Wood J.R., et al. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J. Reprod. Immunol. 2004, 63:51-60.
17. Wood J.R., et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J. Biol. Chem. 2003, 278:26380-26390.
18. Ho C.K., et al. Increased transcription and increased messenger ribonucleic acid (mRNA) stability contribute to increased GATA6 mRNA abundance in polycystic ovary syndrome theca cells. J. Clin. Endocrinol. Metab. 2005, 90:6596-6602.
19. Legro R., et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14956-14960.
20. Strauss J.F., et al. Persistence pays off for PCOS gene prospectors. J. Clin. Endocrinol. Metab. 2012, 97:2286-2288.
21. Chen Z.J., et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 2011, 43:55-59.
22. Shi Y., et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat. Genet. 2012, 44:1020-1025.
23. Goodarzi M.O., et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J. Med. Genet. 2012, 49:90-95.
24. Welt C.K., et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J. Clin. Endocrinol. Metab. 2012, 97:E1342-E1347.
25. Eriksen M.B., et al. Genetic alterations within the DENND1A gene in patients with polycystic ovary syndrome (PCOS). PLoS ONE 2013, 8:e77186.
26. Louwers Y.V., et al. Cross-ethnic meta-analysis of genetic variants for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2013, 98:E2006-E2012.
27. Franks S., et al. Insulin action in the normal and polycystic ovary. Endocrinol. Metab. Clin. North Am. 1999, 28:361-378.
28. Unsal T., et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J. Assist. Reprod. Genet. 2009, 26:205-216.
29. Dolfin E., et al. FSH-receptor Ala307Thr polymorphism is associated to polycystic ovary syndrome and to a higher responsiveness to exogenous FSH in Italian women. J. Assist. Reprod. Genet. 2011, 28:925-930.
30. Fu L., et al. Association study between FSHR Ala307Thr and Ser680Asn variants and polycystic ovary syndrome (PCOS) in Northern Chinese Han women. J. Assist. Reprod. Genet. 2013, 30:717-721.
31. Ioannidis A., et al. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. Mol. Genet. Metab. 2010, 99:174-183.
32. Talbot J.A., et al. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 1996, 81:1979-1983.
33. Mutharasan P., et al. Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J. Clin. Endocrinol. Metab. 2013, 98:E185-E190.
34. Gu B.H., et al. Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. Int. J. Mol. Med. 2010, 26:107-112.
35. Wu X.Q., et al. Association between FSHR polymorphisms and polycystic ovary syndrome among Chinese women in north China. J. Assist. Reprod. Genet. 2014, 31:371-377.
36. Aittomaki K., et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995, 82:959-968.
37. Huhtaniemi I. The Parkes lecture. Mutations of gonadotrophin and gonadotrophin receptor genes: what do they teach us about reproductive physiology?. J. Reprod. Fertil. 2000, 119:173-186.
38. Du J., et al. Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome. Mol. Genet. Metab. 2010, 100:292-295.
39. Conway G.S., et al. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clin. Endocrinol. 1999, 51:97-99.
40. Overbeek A., et al. Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum. Reprod. 2009, 24:2007-2013.
41. Sudo S., et al. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol. Hum. Reprod. 2002, 8:893-899.
42. Simoni M., et al. Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum. Reprod. Update 2002, 8:413-421.
43. Toledo S.P., et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46, XX female. J. Clin. Endocrinol. Metab. 1996, 81:3850-3854.
44. Liu N., et al. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod. Biol. Endocrinol. 2012, 10:36.
45. Latronico A.C., et al. The effect of distinct activating mutations of the luteinizing hormone receptor gene on the pituitary-gonadal axis in both sexes. Clin. Endocrinol. 2000, 53:609-613.
46. Piersma D., et al. LH receptor gene mutations and polymorphisms: an overview. Mol. Cell. Endocrinol. 2007, 260-262:282-286.
47. Capalbo A., et al. The 312N variant of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR) confers up to 2.7-fold increased risk of polycystic ovary syndrome in a Sardinian population. Clin. Endocrinol. 2012, 77:113-119.
48. Rager K.M., Omar H.A. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. Sci. World J. 2006, 6:116-121.
49. Globerman H., Karnieli E. Analysis of the insulin receptor gene tyrosine kinase domain in obese patients with hyperandrogenism, insulin resistance and acanthosis nigricans (type C insulin resistance). Int. J. Obes. Relat. Metab. Disord. 1998, 22:349-353.
50. Urbanek M., et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8573-8578.
51. Villuendas G., et al. Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil. Steril. 2003, 79:219-220.
52. Tucci S., et al. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J. Clin. Endocrinol. Metab. 2001, 86:446-449.
53. Stewart D.R., et al. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J. Clin. Endocrinol. Metab. 2006, 91:4112-4117.
54. Ewens K.G., et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2010, 95:2306-2315.
55. Xie G.B., et al. Microsatellite polymorphism in the fibrillin 3 gene and susceptibility to PCOS: a case-control study and meta-analysis. Reprod. Biomed. Online 2013, 26:168-174.
56. Lee E.J., et al. Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. Fertil. Steril. 2006, 86:380-384.
57. Chen Z.J., et al. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Chin. J. Obstet. Gynecol. 2004, 39:582-585.
58. Jin L., et al. A novel SNP at exon 17 of INSR is associated with decreased insulin sensitivity in Chinese women with PCOS. Mol. Hum. Reprod. 2006, 12:151-155.
59. Mukherjee S., et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur. J. Endocrinol. 2009, 160:855-862.
60. Ramezani Tehrani F., et al. Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. Iran. J. Reprod. Med. 2013, 11:185-194.
61. Lee E.J., et al. A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertil. Steril. 2008, 89:1213-1220.
62. Xu X., et al. Family association study between INSR gene polymorphisms and PCOS in Han Chinese. Reprod. Biol. Endocrinol. 2011, 9:76.
63. Goodarzi M.O., et al. Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil. Steril. 2011, 95:1736-1741.
64. Hanzu F.A., et al. Association of insulin receptor genetic variants with polycystic ovary syndrome in a population of women from Central Europe. Fertil. Steril. 2010, 94:2389-2392.
65. Marat A.L., et al. DENN domain proteins: regulators of Rab GTPases. J. Biol. Chem. 2011, 286:13791-13800.
66. McAllister J.M., et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1519-E1527.
67. Azziz R., et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 2009, 91:456-488.
68. Legro R.S., et al. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2002, 87:2134-2138.
69. Ehrmann D.A., et al. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr. Rev. 1995, 16:322-353.
70. Yildiz B.O., Azziz R. The adrenal and polycystic ovary syndrome. Rev. Endocr. Metab. Disord. 2007, 8:331-342.
71. Cui L., et al. Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Hum. Reprod. 2013, 28:538-544.
72. Wang Z., et al. Variants in DENND1A and LHCGR are associated with endometrioid adenocarcinoma. Gynecol. Oncol. 2012, 2:403-405.
73. Medical College of Wisconsin, Bioinformatics Program, HMGC (2014) QTL report providing DENND1A phenotype and disease descriptions, mapping, a as well as links to markers and candidate genes. http://rgd.mcw.edu/rgdweb/search/qtls.html?term=DENND1A%5Bgene%5D%26speciesType=1.
74. Allaire P.D., et al. The Connecdenn DENN domain: a GEF for Rab35 mediating cargo-specific exit from early endosomes. Mol. Cell 2010, 37:370-382.
75. Basu S., et al. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 2003, 11:11-23.
76. Cowger J.J., et al. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 2007, 26:3378-3386.
77. Yuan S.H., et al. TOX3 regulates calcium-dependent transcription in neurons. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2909-2914.
78. Munir I., et al. Insulin augmentation of 17alpha-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 2004, 145:175-183.
79. Zhang H.Y., et al. Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients. Zhonghua fu chan ke za zhi 2012, 47:19-23. (in Chinese).
80. Ciaraldi T.P. Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity. J. Pediatr. Endocrinol. Metab. 2000, 13(Suppl. 5):1291-1293.
81. Hojlund K., et al. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 2008, 57:357-366.
82. Tee M.K., et al. Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis. Endocrinology 2008, 149:2667-2677.
83. Dunaif A., Fauser B.C. Renaming PCOS - a two-state solution. J. Clin. Endocrinol. Metab. 2013, 98:4325-4328.
84. National Institutes of Health (2012) Evidence-Based Methodology Workshop for Polycystic Ovarian Syndrome December 3-5, 2012, https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf.
85. Legro R.S., et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013, 98:4565-4592.
86. Marat A.L., et al. Connecdenn 3/DENND1C binds actin linking Rab35 activation to the actin cytoskeleton. Mol. Biol. Cell 2012, 23:163-175.
87. Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 2009, 10:513-525.
88. Stenmark H., Olkkonen V.M. The Rab GTPase family. Genome Biol. 2001, 2. Reviews 3007.
89. Noro B., et al. Molecular dissection of the architectural transcription factor HMGA2. Biochemistry 2003, 42:4569-4577.